These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 34503952)
1. Complex Cytochrome P450 Kinetics Due to Multisubstrate Binding and Sequential Metabolism. Part 1. Theoretical Considerations. Wang Z; Paragas EM; Nagar S; Korzekwa K Drug Metab Dispos; 2021 Dec; 49(12):1090-1099. PubMed ID: 34503952 [TBL] [Abstract][Full Text] [Related]
2. Complex Cytochrome P450 Kinetics Due to Multisubstrate Binding and Sequential Metabolism. Part 2. Modeling of Experimental Data. Paragas EM; Wang Z; Korzekwa K; Nagar S Drug Metab Dispos; 2021 Dec; 49(12):1100-1108. PubMed ID: 34503953 [TBL] [Abstract][Full Text] [Related]
4. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Shou M; Mei Q; Ettore MW; Dai R; Baillie TA; Rushmore TH Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):845-53. PubMed ID: 10359672 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Korzekwa KR; Krishnamachary N; Shou M; Ogai A; Parise RA; Rettie AE; Gonzalez FJ; Tracy TS Biochemistry; 1998 Mar; 37(12):4137-47. PubMed ID: 9521735 [TBL] [Abstract][Full Text] [Related]
6. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. Shou M; Dai R; Cui D; Korzekwa KR; Baillie TA; Rushmore TH J Biol Chem; 2001 Jan; 276(3):2256-62. PubMed ID: 11054425 [TBL] [Abstract][Full Text] [Related]
7. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Kenworthy KE; Clarke SE; Andrews J; Houston JB Drug Metab Dispos; 2001 Dec; 29(12):1644-51. PubMed ID: 11717184 [TBL] [Abstract][Full Text] [Related]
8. Differential behavior of the sub-sites of cytochrome 450 active site in binding of substrates, and products (implications for coupling/uncoupling). Narasimhulu S Biochim Biophys Acta; 2007 Mar; 1770(3):360-75. PubMed ID: 17134838 [TBL] [Abstract][Full Text] [Related]
9. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. Yadav J; Paragas E; Korzekwa K; Nagar S Pharmacol Ther; 2020 Feb; 206():107449. PubMed ID: 31836452 [TBL] [Abstract][Full Text] [Related]
10. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions. Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129 [TBL] [Abstract][Full Text] [Related]
11. 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Huang Z; Guengerich FP; Kaminsky LS Carcinogenesis; 1998 May; 19(5):867-72. PubMed ID: 9635876 [TBL] [Abstract][Full Text] [Related]
12. Multiple-ligand binding in CYP2A6: probing mechanisms of cytochrome P450 cooperativity by assessing substrate dynamics. Harrelson JP; Atkins WM; Nelson SD Biochemistry; 2008 Mar; 47(9):2978-88. PubMed ID: 18247580 [TBL] [Abstract][Full Text] [Related]
13. Atypical cytochrome p450 kinetics: implications for drug discovery. Tracy TS Drugs R D; 2006; 7(6):349-63. PubMed ID: 17073518 [TBL] [Abstract][Full Text] [Related]
15. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Spracklin DK; Thummel KE; Kharasch ED Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607 [TBL] [Abstract][Full Text] [Related]
16. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Jornil J; Jensen KG; Larsen F; Linnet K Drug Metab Dispos; 2010 Mar; 38(3):376-85. PubMed ID: 20007670 [TBL] [Abstract][Full Text] [Related]
17. A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theoretical considerations. Nagar S; Jones JP; Korzekwa K Drug Metab Dispos; 2014 Sep; 42(9):1575-86. PubMed ID: 24939654 [TBL] [Abstract][Full Text] [Related]
18. O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. Liu ZQ; Zhu B; Tan YF; Tan ZR; Wang LS; Huang SL; Shu Y; Zhou HH J Pharmacol Exp Ther; 2002 Jan; 300(1):105-11. PubMed ID: 11752104 [TBL] [Abstract][Full Text] [Related]
19. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes. Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067 [TBL] [Abstract][Full Text] [Related]